+1-518-621-2074 | US-Canada Toll Free Contact Us

Promising First-in-class Drugs for Glioblastoma Multiforme to Augment Market Growth

about us

Published on : Oct 17, 2016

ALBANY, NY, Oct 17, 2016: The research study, titled “Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation,” emphasizes on the pathophysiology, symptoms, and an overview of treatment algorithms and pharmacotherapy. In addition, the research study helps in determining the glioblastoma multiforme pipeline, classified on the basis of molecule type, molecular target, and stage of development.

The research study offers a brief analysis regarding the innovations in the glioblastoma multiforme market, focusing on the complete pipeline and current market landscape. Additionally, the deals landscape concerning the first-in-class products, and potential opportunities for in-licensing have been discussed in the scope of the research report. The involvement of microarray-based gene sequencing and gene profiling techniques is expected to boost the demand for glioblastoma multiforme treatments.

The poor outcome for treated patients, the rising number of glioblastoma multiforme cases, and the absence of approved options are some of the factors fuelling the growth of the market. Furthermore, the increasing geriatric population is one of the primary factors augmenting the growth of the glioblastoma multiforme therapeutics market across the globe. The initiatives taken by government and non-government organizations worldwide to create awareness regarding this condition are expected to drive the demand for innovative and effective therapeutics in the next few years. The emergence of several novel therapies, thanks to a promising pipeline is expected to encourage the growth of the overall market throughout the forecast period.

Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=826604

On the other hand, glioblastoma multiforme is extremely resistant to DNA modifying agents, owing to which there are several limitations in the existing therapies. This is expected to restrict the growth of the overall market in the coming years. Nevertheless, the development of biological therapy, immunotherapy, and novel drugs is expected to generate potential opportunities for key players operating in the global market.

The highly polygenic and complex nature of glioblastoma multiforme demands multiple targeted therapies for effective results and enhanced patient prognosis. The fist-in-class targets that have been analyzed in the research study have exhibited efficient profiles and the ability to chemosensitize cancer cells. Key players in the glioblastoma multiforme market are making remarkable efforts to introduce new drugs and gain a competitive advantage in the overall market.

F. Hoffmann La Roche., Exellixis, Inc., Celldex Therapeutics, Inc., Bristol -Myers Squibb Co., and Abbvie, Inc. are some of the leading players operating in the glioblastoma multiforme market across the globe. To offer a clear understanding of the overall market, the research study has highlighted the commercial opportunities in the glioblastoma multiforme deals landscape by identifying latest trends in co-development and licensing deals.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]